AbCellera Biologics Inc. Announces Phase 2 Top‑Line Data Release for ABCL635

What Happened
AbCellera Biologics Inc. (ABCL) filed a Form 8‑K on August 7, 2026 announcing it will release top‑line data from its Phase 2 trial of ABCL635 for moderate‑to‑severe vasomotor symptoms (VMS) due to menopause on Monday, August 10, 2026. The company also said it will hold an investor conference call the same day at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time). The 8‑K includes a press release issued by the company.

Key Details

• Company filed Form 8‑K on August 7, 2026 and issued a press release announcing the readout.
• Top‑line Phase 2 data for ABCL635 (target indication: moderate‑to‑severe VMS due to menopause) to be released on August 10, 2026.
• Investor conference call scheduled for August 10, 2026 at 4:30 a.m. PT / 7:30 a.m. ET.
• The filing was signed by CEO Carl L. G. Hansen, Ph.D.

Why It Matters
This announcement sets a clear near‑term clinical catalyst for AbCellera: the Phase 2 top‑line readout and same‑day investor call will provide the first public summary of ABCL635’s efficacy/safety data in this indication. Investors often view top‑line clinical results as a key event that can affect the company’s development plans and market perception of its pipeline.